Notice of Meeting; Chairpersons, Boards of Scientific Counselors for Institutes/Centers at the NIH, 30409 [E8-11715]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 102 / Tuesday, May 27, 2008 / Notices
pwalker on PROD1PC71 with NOTICES
This application claims use of
suppressive oligonucleotides to
suppress lung inflammation. More
specifically, the application claims use
of suppressive oligonucleotides for the
treatment, prevention, or inhibition of
pneumonia, ARDS, and chronic
bronchitis.
Applications: Vaccine adjuvants,
production of vaccines,
immunotherapeutics.
Development Status: Preclinical
studies have been performed;
oligonucleotides have been synthesized.
Inventors: Dennis Klinman (FDA/
CBER; NCI) and Hiroshi Yamada (CBER/
FDA).
Patent Status: U.S. Provisional
Application No. 60/417,263 filed 08 Oct
2002 (HHS Reference Number E–183–
2002/0–US–01); U.S. Patent Application
No. 10/682,130 filed 07 Oct 2003 (HHS
Reference Number E–183–2002/0–US–
02).
Licensing Status: Available for
exclusive or nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute,
Laboratory of Experimental
Immunology, Immune Modulation
Group, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Method of Treating and Preventing
Infections in Immunocompromised
Subjects With Immunostimulatory CpG
Oligonucleotides
Description of Technology: Primary
disorders of the immune system can be
divided into four categories, (1)
disorders of the humoral immunity, (2)
disorders of cellular immunity, (3)
disorders of phagocytes, and (4)
disorders of complement. In addition,
there are many causes of secondary
immunodeficiency such as treatment
with immunosuppressive or
chemotherapeutic agents, protein-losing
enteropathy, and infection with a
human immunodeficiency virus (HIV).
Generally, immunocompromised
patients are unable to mount an immune
response to a vaccine or an infection in
the same manner as nonimmunocompromised individuals.
Opportunistic infections to which
individuals infected with HIV are
susceptible include bacterial infections
such as salmonellosis, syphilis and
neurosyphilis, tuberculosis (TB), a
VerDate Aug<31>2005
17:22 May 23, 2008
Jkt 214001
typical mycobacterial infection, and
bacillary angiomatosis (cat scratch
disease), fungal infections such as
aspergillosis, candidiasis (thrush, yeast
infection), coccidioidomycosis,
cryptococcal meningitis, and
histoplasmosis, protozoal infections
such as cryptosporidiosis, isosporiasis,
microsporidiosis, Pneumocystis Carinii
pneumonia (PCP), and toxoplasmosis,
viral infections such as Cytomegalovirus
(CMV), hepatitis, herpes simplex (HSV,
genital herpes), herpes zoster (HZV,
shingles), human papilloma virus (HPV,
genital warts, cervical cancer),
Molluscum Contagiosum, oral hairy
leukoplakia (OHL), and progressive
multifocal leukoencephalopathy (PML),
and neoplasms such as Kaposi’s
sarcoma, systemic non-Hodgkin’s
lymphoma (NHL), and primary CNS
lymphoma, among others. These
opportunistic infections remain
principally responsible for the
morbidity and mortality associated with
HIV disease.
This application claims use of
immunostimulatory D-type CpG
oligonucleotides for the treatment of
immunocompromised individuals. More
specifically, the application claims use
of immunostimulatory D-type CpG
oligonucleotides for the treatment of
individuals infected with HIV.
Application: Vaccine adjuvants,
production of vaccines,
immunotherapeutics.
Development Status: Preclinical
studies have been performed;
oligonucleotides have been synthesized.
Inventors: Dennis Klinman (FDA/
CBER; NCI) and Daniela Verthelyi
(FDA/CBER).
Patent Status: U.S. Provisional
Application No. 60/411,944 filed 18 Sep
2002 (HHS Reference No. E–153–2002/
0–US–01); U.S. Patent Application No.
10/666,022 filed 17 Sep 2003 (HHS
Reference No. E–153–2002/0–US–03).
Licensing Status: Available for
exclusive or nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute,
Laboratory of Experimental
Immunology, Immune Modulation
Group, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact John D. Hewes, PhD at 301–435–
3121 or hewesj@mail.nih.gov for more
information.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
30409
Dated: May 15, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–11698 Filed 5–23–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting; Chairpersons,
Boards of Scientific Counselors for
Institutes/Centers at the NIH
Notice is hereby given of a meeting
scheduled by the Deputy Director for
Intramural Research at the National
Institutes of Health (NIH) with the
Chairpersons of the Boards of Scientific
Counselors. The Boards of Scientific
Counselors are advisory groups to the
Scientific Directors of the Intramural
Research Programs at the NIH. This
meeting will take place on June 30,
2008, from 10 a.m. to 3 p.m., at the NIH,
1 Center Drive, Bethesda, MD, Building
1, Wilson Hall. The meeting will
include a discussion of policies and
procedures that apply to the regular
review of NIH intramural scientists and
their work, with special emphasis on
clinical research.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
contact Ms. Colleen Crone at the Office
of Intramural Research, NIH, Building 1,
Room 160, Telephone (301) 496–1921 or
FAX (301) 402–4273 in advance of the
meeting.
Dated: April 30, 2008.
Raynard S. Kington,
Deputy Director, NIH.
[FR Doc. E8–11715 Filed 5–23–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Meeting
Notice is hereby given of a meeting of
the Services Subcommittee of the
Interagency Autism Coordinating
Committee (IACC).
The purpose of the Services
Subcommittee is to review the current
state of services and supports for
individuals with Autism Spectrum
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 73, Number 102 (Tuesday, May 27, 2008)]
[Notices]
[Page 30409]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-11715]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Meeting; Chairpersons, Boards of Scientific Counselors
for Institutes/Centers at the NIH
Notice is hereby given of a meeting scheduled by the Deputy
Director for Intramural Research at the National Institutes of Health
(NIH) with the Chairpersons of the Boards of Scientific Counselors. The
Boards of Scientific Counselors are advisory groups to the Scientific
Directors of the Intramural Research Programs at the NIH. This meeting
will take place on June 30, 2008, from 10 a.m. to 3 p.m., at the NIH, 1
Center Drive, Bethesda, MD, Building 1, Wilson Hall. The meeting will
include a discussion of policies and procedures that apply to the
regular review of NIH intramural scientists and their work, with
special emphasis on clinical research.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should contact Ms. Colleen Crone at the Office of
Intramural Research, NIH, Building 1, Room 160, Telephone (301) 496-
1921 or FAX (301) 402-4273 in advance of the meeting.
Dated: April 30, 2008.
Raynard S. Kington,
Deputy Director, NIH.
[FR Doc. E8-11715 Filed 5-23-08; 8:45 am]
BILLING CODE 4140-01-P
